The benefits, costs and feasibility of a low incidence COVID-19 strategy.

Czypionka T, Iftekhar EN, Prainsack B, Priesemann V, Bauer S, Calero Valdez A, Cuschieri S, Glaab E, Grill E, Krutzinna J, Lionis C, Machado H, Martins C, Pavlakis GN, Perc M, Petelos E, Pickersgill M, Skupin A, Schernhammer E, Szczurek E, Tsiodras S, Willeit P, Wilmes P

Lancet Reg Health Eur 13 (-) 100294 [2022-02-00; online 2022-01-02]

In the summer of 2021, European governments removed most NPIs after experiencing prolonged second and third waves of the COVID-19 pandemic. Most countries failed to achieve immunization rates high enough to avoid resurgence of the virus. Public health strategies for autumn and winter 2021 have ranged from countries aiming at low incidence by re-introducing NPIs to accepting high incidence levels. However, such high incidence strategies almost certainly lead to the very consequences that they seek to avoid: restrictions that harm people and economies. At high incidence, the important pandemic containment measure 'test-trace-isolate-support' becomes inefficient. At that point, the spread of SARS-CoV-2 and its numerous harmful consequences can likely only be controlled through restrictions. We argue that all European countries need to pursue a low incidence strategy in a coordinated manner. Such an endeavour can only be successful if it is built on open communication and trust.

Type: Review

PubMed 35005678

DOI 10.1016/j.lanepe.2021.100294

Crossref 10.1016/j.lanepe.2021.100294

pii: S2666-7762(21)00280-5
pmc: PMC8720492

Publications 9.5.0